Naglazyme Solution For Injection 1Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Naglazyme: Solution for injection (1mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

GALSULFASE is an enzyme replacement. It is used to treat the symptoms of mucopolysaccharidosis VI (also known as MPS VI or Maroteaux-Lamy syndrome). This medicine is not a cure.

In-Depth Information

Naglazyme 1mg/ml Solution for Injection

NDC: 681350020
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from freezing
Naglazyme 1mg/ml Solution for Injection

Reported Side Effects for Naglazyme 1mg/ml Solution for Injection

Corneal Opacification Incidence:
11.0%*
Severity: SEVERE
Onset: DELAYED
Stuffy Nose Incidence:
11.0%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
11.0%*
Severity: MODERATE
Onset: EARLY
Sore Throat Incidence:
11.0%*
Severity: MILD
Onset: DELAYED
Deafness Incidence:
11.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Reflexes Incidence:
11.0%*
Severity: MILD
Onset: DELAYED
Feeling Sick Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Chest Pain Incidence:
16.0%*
Severity: MODERATE
Onset: EARLY
Shortness Of Breath Incidence:
21.0%*
Severity: MODERATE
Onset: EARLY
Conjunctivitis Incidence:
21.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
21.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
21.0%*
Severity: MILD
Onset: RAPID
Ear Pain Incidence:
42.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
42.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
47.0%*
Severity: MILD
Onset: EARLY
Infusion-related Reactions Incidence:
56.0%*
Severity: MODERATE
Onset: RAPID
Antibody Formation Incidence:
98.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Naglazyme

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5